Navigation Links
Alimera Sciences Names European Management Team
Date:11/14/2012

St. Helens and Knowsley School of Nursing, Merseyside, a renal and urology specialist nursing degree from Oxford School of Nursing, Oxford, and a Bachelor of Arts in health studies from Oxford Brookes University.

About ILUVIEN®

ILUVIEN (190 micrograms fluocinolone acetonide intravitreal implant in applicator) is a sustained release intravitreal implant used to treat patients with chronic DME considered insufficiently responsive to available therapies. Each ILUVIEN implant provides a therapeutic effect of up to 36 months by delivering sustained sub-microgram levels of fluocinolone acetonide (FAc). ILUVIEN is injected in the back of the patient's eye to a position that takes advantage of the eye's natural fluid dynamics. The applicator employs a 25-gauge needle, which allows for a self-sealing wound. In Alimera's FAME Study, the most frequently reported adverse drug reactions included cataract operation, cataract and increased ocular pressure.

In July 2010, Alimera submitted a Marketing Authorization Application (MAA) to seven European countries via the Decentralized Procedure (DCP) with the Medicines and Healthcare products Regulatory Agency of the U.K. (MHRA) serving as the Reference Member State (RMS). The MAA included data from two Phase 3 pivotal clinical trials for ILUVIEN conducted by Alimera (collectively known as the FAME Study). The trials involved 956 patients in sites across the United States, Canada, Europe and India to assess the efficacy and safety of ILUVIEN for the treatment of DME. At the end of the DCP, a consensus was reached by the RMS and the other six countries that the MAA for ILUVIEN was approvable. To date, five of the seven countries, Austria, the United Kingdom, Portugal, France and Germany, have granted national licenses for ILUVIEN. ILUVIEN has not been approved by the United States Food and Drug Administration.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Geo
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference
2. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
8. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
9. Neurocrine Biosciences Reports First Quarter 2012 Results
10. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
11. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... , Hologic,s President and Chief Executive Officer, will preside ... October 1, the first day of Breast Cancer Awareness ... Company,s campaign focused on the important benefits of Hologic,s ... the FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... Md. , Sept. 30, 2014  Tasly ... way to modernize medicine, announced today the launch ... of nutraceuticals developed to address men and women ... healthy and vibrant into old age while helping ... includes three condition-specific, whole-food and herb-based formulas, namely, ...
(Date:9/30/2014)... Sept. 30, 2014 STUDY OBJECTIVES ... is to provide an overview of the current ... protein drugs/therapeutics. The key objective is to present ... drugs as an important tool in the treatment ... and future strategies within the protein therapeutics market, ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4
... , PITTSBURGH , June 17 Mylan ... Mylan Pharmaceuticals Inc. received final approval from the U.S. Food ... (ANDA) for Hydroxyzine Hydrochloride Tablets 10 mg, 25 mg and ... therefore, therapeutically equivalent to Pliva,s Hydroxyzine Hydrochloride Tablets, a treatment ...
... Copan unveiled new groundbreaking features of its Walk-Away Specimen ... American Society for Microbiology (ASM) in San Diego, California ... to the market in 2008 with the launch of the ... all microbiology samples. While attending the 110th ASM meeting, Copan ...
Cached Medicine Technology:Mylan Receives Approval for Hydroxyzine Hydrochloride Tablets 2Copan Redefines Automated Specimen Processing with Groundbreaking New Features 2Copan Redefines Automated Specimen Processing with Groundbreaking New Features 3
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... that pull out all the stops to rescue surgical ... but the cost of such heroism is questionable, a ... 5 percent better at saving elderly patients with life-threatening ... with less intensity, said senior author Dr. Amir Ghaferi. ...
(Date:10/2/2014)... discovery by scientists at The University of Nottingham could ... of painkiller. , A drug resulting from the research, ... would offer new hope to sufferers of chronic pain ... effective painkillers are currently available. , The work, led ... Life Sciences, in collaboration with David Bates, Professor of ...
(Date:10/1/2014)... The peptide a small protein beta-amyloid is strongly associated ... unequivocal proof that this peptide is the causal agent ... main obstacle impeding such confirmation is that beta-amyloid is ... it aggregates, that is when it self-assembles to form ... with a single target, beta-amyloid alone, but with multiple ...
(Date:10/1/2014)... new research study published today in the Journal ... patients older than 50 years with moderate or severe ... , Researchers from the University of Melbourne randomly assigned ... pain to no acupuncture or sham or pretend laser ... with participants and acupuncturists blinded to laser and sham ...
(Date:10/1/2014)... co-funded by the Engineering and Physical Sciences Research ... the UK,s vital industrial control systems which run, ... grid, and the rail network. , The ... hackers or malware infiltrating the systems behind our ... in Trustworthy Industrial Control Systems (RITICS), based at ...
Breaking Medicine News(10 mins):Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Medical discovery first step on path to new painkillers 2Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2
... more likely it is to persist, experts say, , , FRIDAY, Sept. ... a harmless rite of passage. But new research suggests it has ... only are people who start to drink at a younger age ... likely to be injured, to be in motor vehicle crashes and ...
... Hopkins recently discovered that a chemical chain reaction that ... humans could mean the difference between normal growth and ... of Cell, describes how organs can grow uncontrollably huge ... , This chain reaction, a domino-like chain of ...
... results of a recent National Academy of Sciences report, ... be restored to the U.S. Department of Energy, says ... nuclear medicine professionals. , Funded by the Department of ... $700,000 report was prompted by a $23 million cut ...
... Roper Industries,Inc. (NYSE: ROP ) announced that ... September 30, 2007, will be released after the market ... discuss these results,has been scheduled for 10:00 AM ET ... via webcast or by dialing +1 888-801-6506 (US/Canada) or ...
... Sept. 21 ChemDiv, Inc. (San Diego) announced,today ... is,undertaking a partnership with the Blokhin Russian Oncology ... the US Department of Energy,(DOE), and the US ... therapies for the prevention and treatment of prostate ...
... LANSING, Mich., Sept. 21 On Sept. 18, ... annual Pinnacle Awards,for Best Practices award reception at ... for Best Practices. "Organizations such as these,are leading ... Pam Byrnes, Pinnacle judge, said. "Michigan needs more,health ...
Cached Medicine News:Health News:Teenage Drinking Can Spell Lasting Trouble 2Health News:Teenage Drinking Can Spell Lasting Trouble 3Health News:Controlling for size may also prevent cancer 2Health News:SNM applauds NAS study showing need to restore federal nuclear medicine research funding 2Health News:SNM applauds NAS study showing need to restore federal nuclear medicine research funding 3Health News:Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership 2Health News:Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership 3Health News:Eight Michigan HMOs, Two Providers, Take Top Honors for Quality Health Care 2Health News:Eight Michigan HMOs, Two Providers, Take Top Honors for Quality Health Care 3
For injecting anesthetics into the muscle cone. 23G x 1 1/2 in (.60 x 38mm)...
... This all digital single plane C-arm ... unprecedented cardiac imaging performance and an expansive ... from cardiac angiography to ECG triggered. ... Flat Detector technology,State of the art dynamic ...
... is a complete vestibular diagnostic system ... movements collected via electrodes. Its Windows-based ... use. Saccade, tracking and Slow Phase ... is facilitated by graphic comparison of ...
For diagnostic and operative treatment of hand and wrist bones. The use of this distraction device allows fracture reduction or widening of the space between bones....
Medicine Products: